Cystic fibrosis lung transplantation

Purpose of review This review summarizes recently published investigations on issues pertaining to cystic fibrosis (CF) lung transplantation. We specifically focus on indications and candidate selection as well as infectious and noninfectious issues specific to CF lung transplant recipients. Recent findings Recent studies have focused on candidate adequacy in high-risk CF patients. We review the current literature on individuals who develop respiratory failure requiring mechanical ventilation and those patients with a pretransplant diagnosis of pulmonary hypertension. Furthermore, the management of peri-operative infectious issues is reviewed including recurrent infections with multidrug-resistant bacterial, mycobacterial, and fungal organisms. Other CF-specific issues addressed include common comorbidities such as CF-related diabetes, gastroesophageal reflux, CF liver disease, and bone metabolism. Summary Lung transplantation is a limited, but potentially life-saving therapeutic option for patients with CF. Optimal candidate selection and awareness of CF-specific issues in the pretransplant and posttransplant setting may lead to better long-term outcomes.

[1]  D. Hadjiliadis Special considerations for patients with cystic fibrosis undergoing lung transplantation. , 2007, Chest.

[2]  L. Sharples,et al.  Risk factors for bronchiolitis obliterans: a systematic review of recent publications. , 2002, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  M. Steele,et al.  Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  R. Porcher,et al.  Determinants of the survival benefit of lung transplantation in patients with chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[5]  R. Houwen,et al.  Defining DIOS and Constipation in Cystic Fibrosis With a Multicentre Study on the Incidence, Characteristics, and Treatment of DIOS , 2010, Journal of pediatric gastroenterology and nutrition.

[6]  C. Merlo,et al.  Impact of U.S. Lung Allocation Score on survival after lung transplantation. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  R. Aris,et al.  Vitamin D Deficiency in Cystic Fibrosis , 2010, International journal of endocrinology.

[8]  S. Keshavjee,et al.  Outcomes of patients with cystic fibrosis undergoing lung transplantation with and without cystic fibrosis‐associated liver cirrhosis * , 2012, Clinical transplantation.

[9]  Shane P. Stenner,et al.  Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosis. , 2011, Chest.

[10]  G. Verleden,et al.  Gastro-oesophageal reflux and aspiration of gastric contents in adult patients with cystic fibrosis , 2008, Gut.

[11]  L. Tsui,et al.  Identification of the cystic fibrosis gene: genetic analysis. , 1989, Science.

[12]  H. Scherstén,et al.  Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[13]  K. Hamilton,et al.  Prevalence of pulmonary hypertension in end-stage cystic fibrosis and correlation with survival. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[14]  S. Force,et al.  Gastroesophageal reflux disease is associated with an increased rate of acute rejection in lung transplant allografts. , 2010, Transplantation proceedings.

[15]  P. Gilligan,et al.  The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome. , 1997, American journal of respiratory and critical care medicine.

[16]  S. Doucette,et al.  Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. , 2010, JAMA.

[17]  J. Lordan,et al.  Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  E. Blackstone,et al.  Should lung transplantation be performed for patients on mechanical respiratory support? The US experience. , 2010, The Journal of thoracic and cardiovascular surgery.

[19]  J. Harkness,et al.  The impact of pan-resistant bacterial pathogens on survival after lung transplantation in cystic fibrosis: results from a single large referral centre. , 2004, The Journal of hospital infection.

[20]  T. Berney,et al.  Combined Pancreatic Islet–Lung Transplantation: A Novel Approach to the Treatment of End‐Stage Cystic Fibrosis , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  Keith McNeil,et al.  International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT). , 1998, American journal of respiratory and critical care medicine.

[22]  R. Kotloff,et al.  Lung transplantation for cystic fibrosis. , 1998, Clinics in chest medicine.

[23]  P. Mordant,et al.  Advances in lung transplantation for cystic fibrosis that may improve outcome. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[24]  T. Nagayasu,et al.  Importance of controlling drug-resistant Pseudomonas aeruginosa infection: experience from lung transplantation in a cystic fibrosis case. , 2010, Internal medicine.

[25]  D. Geddes,et al.  Clinical importance of cystic fibrosis-related diabetes. , 2004, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[26]  R. Bies,et al.  Bioavailability and Population Pharmacokinetics of Voriconazole in Lung Transplant Recipients , 2010, Antimicrobial Agents and Chemotherapy.

[27]  S. Hameed,et al.  Cystic Fibrosis Related Diabetes (CFRD)—The End Stage of Progressive Insulin Deficiency , 2011, Pediatric pulmonology.

[28]  R. Irizarry,et al.  Outcomes of Adults with Cystic Fibrosis Infected with Antibiotic-Resistant Pseudomonas aeruginosa , 2006, Respiration.

[29]  F. Martinez,et al.  International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. , 1998, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[30]  R. Cornwell,et al.  Aspergillus infection in lung transplant recipients with cystic fibrosis: risk factors and outcomes comparison to other types of transplant recipients. , 2003, Chest.

[31]  F. Rea,et al.  Acute cellular rejection and Epstein–Barr virus‐related post‐transplant lymphoproliferative disorder in a pediatric lung transplant with low viral load , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[32]  M. Ireland,et al.  Characteristics of gastroesophageal reflux in adults with cystic fibrosis. , 2010, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[33]  E. Cantu,et al.  J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. , 2004, The Annals of thoracic surgery.

[34]  M. Corey,et al.  Prediction of mortality in patients with cystic fibrosis. , 1992, The New England journal of medicine.

[35]  T. Welte,et al.  Long-Term Azithromycin for Bronchiolitis Obliterans Syndrome After Lung Transplantation , 2008, Transplantation.

[36]  R. Guillemain,et al.  Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. , 2010, Medical mycology.

[37]  P. Corris,et al.  Lung transplantation, gastroesophageal reflux, and fundoplication. , 2010, The Annals of thoracic surgery.

[38]  G. Berry,et al.  Risk factors for the development of obliterative bronchiolitis after lung transplantation. , 1996, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[39]  A. Adler,et al.  Hyperglycemia and Death in Cystic Fibrosis–Related Diabetes , 2011, Diabetes Care.

[40]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report--2010. , 2010, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[41]  C. Combescure,et al.  The Prevalence of Osteoporosis, Osteopenia, and Fractures Among Adults with Cystic Fibrosis: A Systematic Literature Review with Meta-Analysis , 2009, Calcified Tissue International.

[42]  C. Merlo,et al.  Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. , 2010, JAMA.

[43]  Margaret Rosenfeld,et al.  Developing cystic fibrosis lung transplant referral criteria using predictors of 2-year mortality. , 2002, American journal of respiratory and critical care medicine.

[44]  K. Robinson,et al.  Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. , 2010, American journal of respiratory and critical care medicine.

[45]  S. Keshavjee,et al.  Gastroesophageal reflux and lung transplantation. , 2006, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[46]  T. Egan,et al.  Severe osteoporosis before and after lung transplantation. , 1996, Chest.

[47]  B. Button,et al.  Medium-term outcome of fundoplication after lung transplantation. , 2009, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[48]  R. Moss Allergic bronchopulmonary aspergillosis and Aspergillus infection in cystic fibrosis , 2010, Current opinion in pulmonary medicine.

[49]  A. Glanville,et al.  The spectrum of mycobacterial infection after lung transplantation. , 1999, American journal of respiratory and critical care medicine.

[50]  R. Speich,et al.  Effects of sinus surgery in patients with cystic fibrosis after lung transplantation: a 10-year experience , 2004, Transplantation.

[51]  T. Sorrell,et al.  Clinical associations and prevalence of Scedosporium spp. in Australian cystic fibrosis patients: identification of novel risk factors? , 2010, Medical mycology.

[52]  S. Keshavjee,et al.  Survival of Burkholderia cepacia sepsis following lung transplantation in recipients with cystic fibrosis , 2010, Transplant infectious disease : an official journal of the Transplantation Society.

[53]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.